BPH

PVP laser enabling BPH treatment for more patientsLaser photoselective vaporization prostatectomy is permitting surgical intervention for BPH in a widening array of patients, many of whom harbor comorbidities that would ordinarily exclude them from invasive procedures, according to a new multinational report.
CMS issues two codes for BPH implant procedureThe Centers for Medicare & Medicaid Services has issued two new codes that describe the UroLift implant procedure for the treatment of enlarged prostate in the April 2014 Update of the Hospital Outpatient Prospective Payment System (OPPS).
December 2013 Urology Products and ServicesThe latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.
Urology Product Preview November 2013Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.
FDA approves label addition for PDE-5 inhibitor
FDA approves label addition for PDE-5 inhibitorThe FDA has approved a product label addition for the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) that involves its use with finasteride (Proscar).
Thulium vapoenucleation found safe, efficacious in BPHThulium vapoenucleation of the prostate provided significant and durable symptomatic improvement in benign prostatic obstruction, long-term follow-up of a clinical series showed.
Lift device for BPH earns FDA approvalThe FDA has authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.
Genetic variants linked to lower urinary tract symptoms in African-AmericansIn a study of African-American men, researchers say they’ve linked two genetic variants to severity of lower urinary tract symptoms related to BPH, giving scientists insight into the higher risk facing African-Americans.
Advances in TURP: Focus on the scienceMost urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPH
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPHA new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.